Lv1
50 积分 2021-01-10 加入
Spatial Profiling of Patient-Matched HER2 Positive Gastric Cancer Reveals Resistance Mechanisms to Trastuzumab and Trastuzumab Deruxtecan
3天前
已完结
460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
5天前
待确认
RNA Editing-Mediated Correction of TP53 Nonsense Mutations via Lipid Nanoparticle-Delivered Circular ADAR-Recruiting RNAs
12天前
已完结
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer
17天前
已完结
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer
17天前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
17天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
24天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
25天前
已完结
Targetable S100-RAGE signaling mediates intrinsic trastuzumab deruxtecan resistance in metastatic breast cancer
25天前
已完结
皖公网安备34019202002308
